201 related articles for article (PubMed ID: 35582525)
1. Auranofin and its analogs as prospective agents for the treatment of colorectal cancer.
Massai L; Cirri D; Marzo T; Messori L
Cancer Drug Resist; 2022; 5(1):1-14. PubMed ID: 35582525
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the design of analogs of auranofin endowed with anticancer potential.
Vitali V; Massai L; Messori L
Expert Opin Drug Discov; 2024 May; ():1-13. PubMed ID: 38803122
[TBL] [Abstract][Full Text] [Related]
3. Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action.
Lima JC; Rodriguez L
Anticancer Agents Med Chem; 2011 Dec; 11(10):921-8. PubMed ID: 21864238
[TBL] [Abstract][Full Text] [Related]
4. The leading established metal-based drugs: a revisitation of their relevant physico-chemical data.
Cirri D; Fabbrini MG; Pratesi A; Ciofi L; Massai L; Marzo T; Messori L
Biometals; 2019 Oct; 32(5):813-817. PubMed ID: 31473877
[TBL] [Abstract][Full Text] [Related]
5. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications.
Sannella AR; Casini A; Gabbiani C; Messori L; Bilia AR; Vincieri FF; Majori G; Severini C
FEBS Lett; 2008 Mar; 582(6):844-7. PubMed ID: 18294965
[TBL] [Abstract][Full Text] [Related]
6. A new target for gold(I) compounds: glutathione-S-transferase inhibition by auranofin.
De Luca A; Hartinger CG; Dyson PJ; Lo Bello M; Casini A
J Inorg Biochem; 2013 Feb; 119():38-42. PubMed ID: 23183361
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment.
Mahmud KM; Niloy MS; Shakil MS; Islam MA
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452256
[TBL] [Abstract][Full Text] [Related]
8. Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.
Fernandez-Vega L; Ruiz Silva VA; Domínguez-González TM; Claudio-Betancourt S; Toro-Maldonado RE; Capre Maso LC; Ortiz KS; Pérez-Verdejo JA; González JR; Rosado-Fraticelli GT; Meléndez FP; Betancourt Santiago FM; Rivera-Rivera DA; Navarro CM; Bruno Chardón AC; Vera AO; Tinoco AD
Inorganics (Basel); 2020 Feb; 8(2):. PubMed ID: 34046448
[TBL] [Abstract][Full Text] [Related]
9. Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections.
Feng L; Pomel S; Latre de Late P; Taravaud A; Loiseau PM; Maes L; Cho-Ngwa F; Bulman CA; Fischer C; Sakanari JA; Ziniel PD; Williams DL; Davioud-Charvet E
Molecules; 2020 Nov; 25(21):. PubMed ID: 33139647
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide CRISPR Screen Reveal Targets of Chiral Gold(I) Anticancer Compound in Mammalian Cells.
Kim JH; Ofori S; Tagmount A; Vulpe CD; Awuah SG
ACS Omega; 2022 Nov; 7(43):39197-39205. PubMed ID: 36340096
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms and proposed targets for selected anticancer gold compounds.
Casini A; Messori L
Curr Top Med Chem; 2011; 11(21):2647-60. PubMed ID: 22039866
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt
Tolbatov I; Cirri D; Marchetti L; Marrone A; Coletti C; Re N; La Mendola D; Messori L; Marzo T; Gabbiani C; Pratesi A
Front Chem; 2020; 8():812. PubMed ID: 33195032
[TBL] [Abstract][Full Text] [Related]
13. Auranofin.
Davis P
Clin Rheum Dis; 1984 Aug; 10(2):369-83. PubMed ID: 6239742
[TBL] [Abstract][Full Text] [Related]
14. A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition.
Ilari A; Baiocco P; Messori L; Fiorillo A; Boffi A; Gramiccia M; Di Muccio T; Colotti G
Amino Acids; 2012 Feb; 42(2-3):803-11. PubMed ID: 21833767
[TBL] [Abstract][Full Text] [Related]
15. Gold as a Possible Alternative to Platinum-Based Chemotherapy for Colon Cancer Treatment.
Mármol I; Quero J; Rodríguez-Yoldi MJ; Cerrada E
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31195711
[TBL] [Abstract][Full Text] [Related]
16. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin.
Darabi F; Marzo T; Massai L; Scaletti F; Michelucci E; Messori L
J Inorg Biochem; 2015 Aug; 149():102-7. PubMed ID: 25865000
[TBL] [Abstract][Full Text] [Related]
17. Auranofin: a unique oral chrysotherapeutic agent.
Blodgett RC; Heuer MA; Pietrusko RG
Semin Arthritis Rheum; 1984 Feb; 13(3):255-73. PubMed ID: 6427927
[TBL] [Abstract][Full Text] [Related]
18. Auranofin and its Analogues Show Potent Antimicrobial Activity against Multidrug-Resistant Pathogens: Structure-Activity Relationships.
Marzo T; Cirri D; Pollini S; Prato M; Fallani S; Cassetta MI; Novelli A; Rossolini GM; Messori L
ChemMedChem; 2018 Nov; 13(22):2448-2454. PubMed ID: 30252208
[TBL] [Abstract][Full Text] [Related]
19. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
20. Formation of a cationic gold(I) complex and disulfide by oxidation of the antiarthritic gold drug auranofin.
Mohamed AA; Chen J; Bruce AE; Bruce MR; Krause Bauer JA; Hill DT
Inorg Chem; 2003 Apr; 42(7):2203-5. PubMed ID: 12665352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
